Chief Scientific Officer
Per Falk is responsible for overseeing all of Ferring’s Research, Development & Regulatory activities. Dr. Falk’s career includes positions as Associate Professor/Lecturer at the Dept. of Medicine at the Karolinska Institute in Stockholm and adjunct Associate Professor at the Department of Molecular Biology and Pharmacology at Washington University School of Medicine in St. Louis. In 1998, he joined AstraZeneca where he served as Head of Gastrointestinal Pharmacology and Molecular Biology. Dr. Falk joined Novo Nordisk in 2002 as VP of Experimental Medicine. From 2004, he served as VP for clinical development, medical affairs and regulatory affairs in Japan and US before returning to Denmark to serve as Senior Vice President Biopharmaceuticals Research. Dr. Falk trained and practiced medicine in Gothenburg and Stockholm and has a Ph.D. in Biochemistry from Gothenburg University.